Pharvaris (PHVS) EBIT Growth (1y) (2021 - 2026)
Powered by 
Analysis
Pharvaris (PHVS) EBIT Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 10.14% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 269.85% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1,528.74% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -36.55% |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 99.51% |
| 10 | Pharvaris | 2.15 Bn | 1.78 Bn | 85,072.10 | -7.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.14% |
| Mar 31, 2026 | -16.80% |
| Dec 31, 2025 | 32.35% |
| Sep 30, 2025 | -11.40% |
| Jun 30, 2025 | -60.46% |
| Mar 31, 2025 | -44.28% |
| Dec 31, 2024 | 331,995,282.81% |
| Sep 30, 2024 | -45.94% |
| Jun 30, 2024 | -34.53% |
| Mar 31, 2024 | -35.96% |
| Dec 31, 2023 | -153.78% |
| Sep 30, 2023 | -26.36% |
| Jun 30, 2023 | -125.21% |
| Mar 31, 2023 | -4.01% |
| Dec 31, 2022 | -134.21% |
| Sep 30, 2022 | -43.59% |
| Jun 30, 2022 | 42.41% |
| Mar 31, 2022 | -52.25% |
| Dec 31, 2021 | 57.79% |
| Sep 30, 2021 | -114.52% |